AbbVie to Host Virtual Immunology Strategic Update
Get Alerts ABBV Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.8%
Revenue Growth %: +8.8%
Join SI Premium – FREE
NORTH CHICAGO, Ill., Dec. 1, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) will host a virtual immunology strategic update for investors on Monday, December 14, 2020 at 9:00 a.m. Central time. Richard A. Gonzalez, chairman of the board and chief executive officer, and members of the executive leadership team will present on AbbVie's immunology business and pipeline.
A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the webcast will be available later that day.
About AbbVieAbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
View original content:http://www.prnewswire.com/news-releases/abbvie-to-host-virtual-immunology-strategic-update-301181943.html
SOURCE AbbVie
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abbvie (ABBV) PT Raised to $300 at BMO Capital
- TCS Becomes Technology and Innovation Partner to New York's New Terminal One at JFK Airport
- H1 2026 Operations Update
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share